alexa Pioglitazone in the management of Type 2 diabetes and beyond
Pharmaceutical Sciences

Pharmaceutical Sciences

Research & Reviews: Journal of Hospital and Clinical Pharmacy

Author(s): Assoz Prof PrivDoz Drmed

Abstract Share this page

The prevalence of Type 2 diabetes mellitus is increasing rapidly and this disease has become an alarming healthcare problem in recent years. Both insulin resistance and β-cell dysfunction play important roles in the pathophysiology of Type 2 diabetes mellitus. Pioglitazone, a thiazolidinedione, has been demonstrated to improve both impairments and is currently used as monotherapy or in combination with insulin, sulfonylureas or metformin for the treatment of Type 2 diabetes mellitus. Clinical studies have confirmed the efficacy, safety and tolerability profile of pioglitazone and, furthermore, a large outcomes trial has recently demonstrated positive cardiovascular effects. Ongoing studies have shown that pioglitazone has possible applications beyond the treatment of diabetes in conditions such as nonalcoholic steatohepatitis or polycystic ovarian syndrome. This review provides an overview of the pharmacology, clinical efficacy and safety of pioglitazone, focusing primarily on the most recent data.

This article was published in Therapy and referenced in Research & Reviews: Journal of Hospital and Clinical Pharmacy

Relevant Expert PPTs

Relevant Speaker PPTs

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords